BasicPage(2)
This activity has been updated
Refreshing restarts the activity from the beginning; answers you have given so far are not kept.
Advances in Cardiovascular Disease Management
This activity is designed to provide healthcare professionals with evidence-based updates on contemporary approaches to cardiovascular disease prevention and treatment.
Accreditation
Accredited by the Accreditation Council for Continuing Medical Education (ACCME)
Activity ID: CME-2026-CV-001
Faculty
Dr. Sarah Martinez, MD, FACC
Director of Cardiovascular Research, University Medical Center
Dr. James Chen, MD, PhD
Professor of Cardiology, Harvard Medical School
Learning Objectives
- Identify the latest evidence-based guidelines for managing patients with heart failure
- Evaluate the role of novel anticoagulation therapies in atrial fibrillation management
- Apply risk stratification tools to optimize cardiovascular disease prevention strategies
- Recognize key pharmacological updates in lipid management and diabetes care
Completion Requirements
- Watch educational video (minimum 80% completion required)
- Complete all assessment questions
- Achieve a passing score of 70% or higher
- Provide participant information for certificate
Educational Content
Introduction to Cardiovascular Disease Management
Cardiovascular disease (CVD) remains the leading cause of mortality worldwide. Recent advances in both pharmacological and interventional therapies have significantly improved patient outcomes. This module reviews the latest evidence-based approaches to CVD prevention and treatment.
Key Topics Covered
- Heart Failure Management: Updated guidelines on medication optimization, including SGLT2 inhibitors and ARNI therapy
- Heart Failure Management: Updated guidelines on medication optimization, including SGLT2 inhibitors and ARNI therapy
- Heart Failure Management: Updated guidelines on medication optimization, including SGLT2 inhibitors and ARNI therapy
|
Heart Failure Management: Updated guidelines on medication optimization, including SGLT2 inhibitors and ARNI therapy |
Atrial Fibrillation: Novel oral anticoagulants (NOACs) and stroke prevention strategies |
|
Lipid Management: Role of PCSK9 inhibitors and combination therapies |
Risk Stratification: Application of pooled cohort equations and CAC scoring |
Clinical Pearls
When initiating therapy for heart failure with reduced ejection fraction (HFrEF), consider the "four pillars" approach: ACE inhibitors/ARBs/ARNI, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. Early implementation of guideline-directed medical therapy (GDMT) has been shown to reduce mortality by up to 50%.
Checking engagement time...
Assessment Complete
Performance Summary
- Questions Answered:
- Correct Answers:
- Incorrect Answers:
- Pass Threshold:
- Your Score:
Participant Information
Please provide your information to receive your CME certificate.CME Certificate
Certificate Generated Successfully! Your certificate has been created and is ready for download. A copy has also been sent to .